Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge

References

• Lou H, Wang C, Zhang L. Endotype-driven precision medicine in chronic rhinosinusitis. Expert Rev Clin Immunol. 2019;15(11):1171–1183.
   PubMed Web of Science ®Google Scholar
• Wang C, Yan B, Zhang L. The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2020;16(3):293–310.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582–1605. DOI:10.1111/all.14318
   PubMed Web of Science ®Google Scholar
• Cai S, Xu S, Lou H, et al. Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis. J Allergy Clin Immunol Pract. 2022;10(7):1876–1886. e1877. DOI:10.1016/j.jaip.2022.02.034
   PubMed Web of Science ®Google Scholar
• Peters AT, Han JK, Hellings P, et al. Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9(6):2461–2471. DOI:10.1016/j.jaip.2021.01.031
   PubMed Web of Science ®Google Scholar
• Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2022;149(4):1286–1295. DOI:10.1016/j.jaci.2021.09.009
   PubMedGoogle Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. DOI:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Roland LT, Regenberg A, Luong AU, et al. Biologics for chronic rhinosinusitis with nasal polyps: economics and ethics. Int Forum Allergy Rhinol. 2021;11(11):1524–1528. DOI:10.1002/alr.22864
   PubMed Web of Science ®Google Scholar
• Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73(7):1459–1469. DOI:10.1111/all.13411
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456. DOI:10.1016/j.jaci.2015.12.1324
   PubMed Web of Science ®Google Scholar
• Delemarre T, Holtappels G, De Ruyck N, et al. A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2021;147(1):179–88 e172. DOI:10.1016/j.jaci.2020.08.036
   PubMed Web of Science ®Google Scholar
• Poposki JA, Klingler AI, Stevens WW, et al. Elevation of activated neutrophils in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2022;149(5):1666–1674. DOI:10.1016/j.jaci.2021.11.023
   PubMed Web of Science ®Google Scholar
• Soyka MB, Ryser FS, Bruhlmann C, et al. Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis. Allergy. 2023;78(4):1036–1046. DOI:10.1111/all.15532
   PubMed Web of Science ®Google Scholar
• Kong IG, Kim DK, Eun KM, et al. Receptor activator of nuclear factor κB ligand is a biomarker for osteitis of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2020;10(3):364–373. DOI:10.1002/alr.22481
   PubMed Web of Science ®Google Scholar
• Fujieda S, Matsune S, Takeno S, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy. 2022;77(1):186–196. DOI:10.1111/all.14906
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022;149(5):1711–1721. DOI:10.1016/j.jaci.2021.10.040
   PubMed Web of Science ®Google Scholar
• Damask C, Chen M, Holweg CTJ, et al. Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis. Am J Rhinol Allergy. 2022;36(1):135–141. DOI:10.1177/19458924211030486
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309–1317. DOI:10.1016/j.jaci.2021.08.030
   PubMed Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–1153. DOI:10.1016/S2213-2600(21)00097-7
   PubMed Web of Science ®Google Scholar
• Yang D, Huang T, Liu B, et al. Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy. J Asthma. 2020;57(1):79–81. DOI:10.1080/02770903.2018.1545857
   PubMed Web of Science ®Google Scholar
• Mummler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol Pract. 2021;9(3):1177–1185. DOI:10.1016/j.jaip.2020.09.014
   PubMedGoogle Scholar
• Shrimanker R, Keene O, Hynes G, et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. DOI:10.1164/rccm.201903-0599LE
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. DOI:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. DOI:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. DOI:10.1164/rccm.201208-1414OC
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–64 e151. DOI:10.1016/j.jaip.2018.04.043
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kavanagh J, d’Ancona G, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093–2096. DOI:10.1016/j.jaip.2021.01.008
   PubMed Web of Science ®Google Scholar
• Chibana K, Trudeau JB, Mustovich AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy. 2008;38(6):936–946. DOI:10.1111/j.1365-2222.2008.02969.x
   PubMed Web of Science ®Google Scholar
• Stein NC, Kreutzmann C, Zimmermann SP, et al. Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res. 2008;23(5):750–758. DOI:10.1359/jbmr.080203
   PubMed Web of Science ®Google Scholar
• Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74(4):743–752. DOI:10.1111/all.13685
   PubMed Web of Science ®Google Scholar
• Xu X, Li J, Zhang Y, et al. Arachidonic acid 15-lipoxygenase: effects of its expression, metabolites, and genetic and epigenetic variations on airway inflammation. Allergy Asthma Immunol Res. 2021;13(5):684–696.
   PubMed Web of Science ®Google Scholar
• Yan B, Lou H, Wang Y, et al. Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(2):455–469. DOI:10.1016/j.jaci.2019.03.026
   PubMed Web of Science ®Google Scholar